{
    "info": {
        "nct_id": "NCT05870761",
        "official_title": "Phase II Trial of Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma",
        "inclusion_criteria": "* Participant must have recurrent or persistent uterine serous carcinoma based on previous biopsy or surgery, and have previously received at least carboplatin/paclitaxel. Mixed and carcinosarcoma histology cases will be eligible if there is a serous component in the tumor\n* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 1\n* Participant must be >= 18 years of age\n* Patient has archival tumor tissue available or a fresh biopsy of recurrent or persistent tumor must be obtained prior to study treatment initiation\n* Patient must have measurable disease by RECIST\n* No more than three prior chemotherapy regimens (does not include chemoradiation) are permitted. One of the previous lines of treatment must include carboplatin and paclitaxel\n* Prior PD1/PDL1 inhibitors (including single-agent pembrolizumab, other immunotherapy agents, or combination pembrolizumab and lenvatinib) therapy will be allowed if the patient did not have immune associated toxicity leading to discontinuation.\n\n  * Patients who have progressed on prior PD1/PDL1 inhibitors may be allowed to participate if the study PI and treating physician deem it to be within the patient's best interest.\n* Prior chemoradiation therapy for adjuvant treatment or pelvic recurrence is permitted. Chemotherapy in this setting, is not counted as prior line of chemotherapy\n* Absolute neutrophil count >= 1,500/uL\n* Platelets >= 100,000/uL\n* Hemoglobin >= 9 g/dL\n* Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance >= 60 mL/min using the Cockcroft-Gault equation\n* Total bilirubin =< 1.5 x ULN (=< 2.0 in patients with known Gilberts syndrome) OR direct bilirubin =< 1 x ULN\n* Aspartate aminotransferase and alanine aminotransferase =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN\n* International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants\n* Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants\n* Participant receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy and dose < 10 mg of prednisone or equivalent\n* Participant must be able to take oral medications\n* Participant must agree to not donate blood during the study or for 120 days after the last dose of study treatment\n* If of childbearing potential, has a negative serum pregnancy test within 7 days prior to taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 180 days (6 months) after the last dose of study treatment or be of non-childbearing potential. Non childbearing potential is defined as follows (by other than medical reasons):\n\n  * >= 45 years of age and has not had menses for > 1 year\n  * Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation\n  * Surgically sterile as defined as post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 180 days after the last dose of study treatment. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient\n* Participant must agree to not breastfeed during the study or for 120 days after the last dose of study treatment\n* Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent\n* Must have recovered to =< grade 1 from all toxicities related to prior treatment that are deemed clinically relevant in the opinion of the investigator at time of enrollment\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Participant must not be simultaneously enrolled in any interventional clinical trial\n* Participant must not have had major surgery =< 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects\n* Participant must not have received investigational therapy =< 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior initiating protocol therapy\n* Participant's last treatment with platinum based chemotherapy was =< 4 weeks from initiation of protocol therapy\n* Participant has had radiation therapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy\n* Participant must not have a known hypersensitivity to niraparib and dostarlimab components or excipients\n* Participant must not have previously progressed on PARP inhibitor\n* Participant experienced >= grade 3 immune-related adverse event (AE) with prior immunotherapy, with the exception of non-clinically significant lab abnormalities\n* Participant must not have received a transfusion (platelets or red blood cells) =< 4 weeks prior to initiating protocol therapy\n* Participant must not have received colony-stimulating factors (eg, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy\n* Participant has had any known grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment\n* Participant must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)\n* Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled hypertension, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent. Participants with hypertension but be well controlled before first dose of niraparib\n* Participant must not have had diagnosis, detection, or treatment of another type of cancer =< 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)\n* Participant must not have a known history of brain or leptomeningeal metastases\n* Participant has a diagnosis of immunodeficiency or has received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy\n* Participant has a known history of human immunodeficiency virus (type 1 or 2 antibodies)\n* Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)\n* Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement hormone therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not an exclusion criterion\n* Participant must not have a history of interstitial lung disease\n* Participant is considered a poor medical risk that would interfere with cooperation with the requirements of the study\n* Participant has received a live vaccine within 30 days of initiating protocol therapy\n* Participant has a history of posterior reversible encephalopathy syndrome (PRES)",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Patients who have progressed on prior PD1/PDL1 inhibitors may be allowed to participate if the study PI and treating physician deem it to be within the patient's best interest.",
            "criterions": [
                {
                    "exact_snippets": "Patients who have progressed on prior PD1/PDL1 inhibitors",
                    "criterion": "progression on prior PD1/PDL1 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "history of progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if the study PI and treating physician deem it to be within the patient's best interest",
                    "criterion": "study PI and treating physician approval",
                    "requirements": [
                        {
                            "requirement_type": "approval",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count >= 1,500/uL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count >= 1,500/uL",
                    "criterion": "absolute neutrophil count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must have recurrent or persistent uterine serous carcinoma based on previous biopsy or surgery, and have previously received at least carboplatin/paclitaxel. Mixed and carcinosarcoma histology cases will be eligible if there is a serous component in the tumor",
            "criterions": [
                {
                    "exact_snippets": "Participant must have recurrent or persistent uterine serous carcinoma",
                    "criterion": "uterine serous carcinoma",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease_status",
                            "expected_value": [
                                "recurrent",
                                "persistent"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "based on previous biopsy or surgery",
                    "criterion": "diagnosis confirmation method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "biopsy",
                                "surgery"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "have previously received at least carboplatin/paclitaxel",
                    "criterion": "prior treatment with carboplatin/paclitaxel",
                    "requirements": [
                        {
                            "requirement_type": "treatment_history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Mixed and carcinosarcoma histology cases will be eligible if there is a serous component in the tumor",
                    "criterion": "tumor histology serous component",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status of =< 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status of =< 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must be >= 18 years of age",
            "criterions": [
                {
                    "exact_snippets": "Participant must be >= 18 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient has archival tumor tissue available or a fresh biopsy of recurrent or persistent tumor must be obtained prior to study treatment initiation",
            "criterions": [
                {
                    "exact_snippets": "archival tumor tissue available",
                    "criterion": "archival tumor tissue",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "fresh biopsy of recurrent or persistent tumor must be obtained prior to study treatment initiation",
                    "criterion": "fresh biopsy of recurrent or persistent tumor",
                    "requirements": [
                        {
                            "requirement_type": "availability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "prior to study treatment initiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient must have measurable disease by RECIST",
            "criterions": [
                {
                    "exact_snippets": "measurable disease by RECIST",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "RECIST"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* No more than three prior chemotherapy regimens (does not include chemoradiation) are permitted. One of the previous lines of treatment must include carboplatin and paclitaxel",
            "criterions": [
                {
                    "exact_snippets": "No more than three prior chemotherapy regimens (does not include chemoradiation) are permitted",
                    "criterion": "number of prior chemotherapy regimens",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "regimens"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "One of the previous lines of treatment must include carboplatin and paclitaxel",
                    "criterion": "previous lines of treatment",
                    "requirements": [
                        {
                            "requirement_type": "inclusion of agents",
                            "expected_value": [
                                "carboplatin",
                                "paclitaxel"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior PD1/PDL1 inhibitors (including single-agent pembrolizumab, other immunotherapy agents, or combination pembrolizumab and lenvatinib) therapy will be allowed if the patient did not have immune associated toxicity leading to discontinuation.",
            "criterions": [
                {
                    "exact_snippets": "Prior PD1/PDL1 inhibitors (including single-agent pembrolizumab, other immunotherapy agents, or combination pembrolizumab and lenvatinib) therapy will be allowed",
                    "criterion": "prior PD1/PDL1 inhibitor therapy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "if the patient did not have immune associated toxicity leading to discontinuation",
                    "criterion": "immune associated toxicity leading to discontinuation",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets >= 100,000/uL",
            "criterions": [
                {
                    "exact_snippets": "Platelets >= 100,000/uL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "uL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior chemoradiation therapy for adjuvant treatment or pelvic recurrence is permitted. Chemotherapy in this setting, is not counted as prior line of chemotherapy",
            "criterions": [
                {
                    "exact_snippets": "Prior chemoradiation therapy for adjuvant treatment or pelvic recurrence is permitted",
                    "criterion": "prior chemoradiation therapy for adjuvant treatment or pelvic recurrence",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Chemotherapy in this setting, is not counted as prior line of chemotherapy",
                    "criterion": "chemotherapy for adjuvant treatment or pelvic recurrence",
                    "requirements": [
                        {
                            "requirement_type": "prior line counting",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin >= 9 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin >= 9 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 9,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Serum creatinine =< 1.5 x upper limit of normal (ULN) or calculated creatinine clearance >= 60 mL/min using the Cockcroft-Gault equation",
            "criterions": [
                {
                    "exact_snippets": "Serum creatinine =< 1.5 x upper limit of normal (ULN)",
                    "criterion": "serum creatinine",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "calculated creatinine clearance >= 60 mL/min using the Cockcroft-Gault equation",
                    "criterion": "calculated creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase and alanine aminotransferase =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase ... =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN",
                    "criterion": "aspartate aminotransferase (AST)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alanine aminotransferase ... =< 2.5 x ULN unless liver metastases are present, in which case they must be =< 5 x ULN",
                    "criterion": "alanine aminotransferase (ALT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver metastases)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants",
                    "criterion": "INR or PT",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless patient is receiving anticoagulant therapy as long as PT or partial thromboplastin (PTT) is within therapeutic range of intended use of anticoagulants",
                    "criterion": "PT or PTT (in patients receiving anticoagulant therapy)",
                    "requirements": [
                        {
                            "requirement_type": "therapeutic range",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin =< 1.5 x ULN (=< 2.0 in patients with known Gilberts syndrome) OR direct bilirubin =< 1 x ULN",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin =< 1.5 x ULN (=< 2.0 in patients with known Gilberts syndrome)",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (Gilberts syndrome)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.0,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "direct bilirubin =< 1 x ULN",
                    "criterion": "direct bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "x ULN"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Activated partial thromboplastin time (aPTT) =< 1.5 x ULN unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
            "criterions": [
                {
                    "exact_snippets": "Activated partial thromboplastin time (aPTT) =< 1.5 x ULN",
                    "criterion": "activated partial thromboplastin time (aPTT)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unless patient is receiving anticoagulant therapy as long as PT or PTT is within therapeutic range of intended use of anticoagulants",
                    "criterion": "prothrombin time (PT) or partial thromboplastin time (PTT) in patients receiving anticoagulant therapy",
                    "requirements": [
                        {
                            "requirement_type": "therapeutic range",
                            "expected_value": "within therapeutic range of intended use of anticoagulants"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy and dose < 10 mg of prednisone or equivalent",
            "criterions": [
                {
                    "exact_snippets": "Participant receiving corticosteroids may continue as long as their dose is stable for least 4 weeks prior to initiating protocol therapy",
                    "criterion": "corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "stability duration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "dose < 10 mg of prednisone or equivalent",
                    "criterion": "corticosteroid dose",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 10,
                                "unit": "mg prednisone or equivalent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must agree to not donate blood during the study or for 120 days after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Participant must agree to not donate blood during the study or for 120 days after the last dose of study treatment",
                    "criterion": "blood donation",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "abstinence period",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "during the study"
                                    },
                                    {
                                        "operator": ">=",
                                        "value": 120,
                                        "unit": "days after the last dose of study treatment"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must be able to take oral medications",
            "criterions": [
                {
                    "exact_snippets": "Participant must be able to take oral medications",
                    "criterion": "ability to take oral medications",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* >= 45 years of age and has not had menses for > 1 year",
            "criterions": [
                {
                    "exact_snippets": ">= 45 years of age",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "age",
                            "expected_value": {
                                "operator": ">=",
                                "value": 45,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has not had menses for > 1 year",
                    "criterion": "menses",
                    "requirements": [
                        {
                            "requirement_type": "absence_duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* If of childbearing potential, has a negative serum pregnancy test within 7 days prior to taking study medication and agrees to abstain from activities that could result in pregnancy from enrollment through 180 days (6 months) after the last dose of study treatment or be of non-childbearing potential. Non childbearing potential is defined as follows (by other than medical reasons):",
            "criterions": [
                {
                    "exact_snippets": "If of childbearing potential, has a negative serum pregnancy test within 7 days prior to taking study medication",
                    "criterion": "serum pregnancy test",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "negative"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "within 7 days prior to taking study medication"
                        }
                    ]
                },
                {
                    "exact_snippets": "agrees to abstain from activities that could result in pregnancy from enrollment through 180 days (6 months) after the last dose of study treatment",
                    "criterion": "abstinence from activities that could result in pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": "from enrollment through 180 days (6 months) after the last dose of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "be of non-childbearing potential. Non childbearing potential is defined as follows (by other than medical reasons):",
                    "criterion": "childbearing potential",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": "non-childbearing potential"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients who have been amenorrhoeic for < 2 years without history of a hysterectomy and oophorectomy must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation",
            "criterions": [
                {
                    "exact_snippets": "Patients who have been amenorrhoeic for < 2 years",
                    "criterion": "amenorrhoea duration",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "years"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "without history of a hysterectomy",
                    "criterion": "history of hysterectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "without ... oophorectomy",
                    "criterion": "history of oophorectomy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a follicle stimulating hormone value in the postmenopausal range upon screening evaluation",
                    "criterion": "follicle stimulating hormone value",
                    "requirements": [
                        {
                            "requirement_type": "range",
                            "expected_value": "postmenopausal range"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must be able to understand the study procedures and agree to participate in the study by providing written informed consent",
            "criterions": [
                {
                    "exact_snippets": "Participant must be able to understand the study procedures",
                    "criterion": "ability to understand study procedures",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "agree to participate in the study by providing written informed consent",
                    "criterion": "informed consent",
                    "requirements": [
                        {
                            "requirement_type": "provision of written informed consent",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have recovered to =< grade 1 from all toxicities related to prior treatment that are deemed clinically relevant in the opinion of the investigator at time of enrollment",
            "criterions": [
                {
                    "exact_snippets": "Must have recovered to =< grade 1 from all toxicities related to prior treatment",
                    "criterion": "toxicities related to prior treatment",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "grade"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "that are deemed clinically relevant in the opinion of the investigator at time of enrollment",
                    "criterion": "clinical relevance of toxicities (as judged by investigator)",
                    "requirements": [
                        {
                            "requirement_type": "investigator judgment",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must agree to not breastfeed during the study or for 120 days after the last dose of study treatment",
            "criterions": [
                {
                    "exact_snippets": "Participant must agree to not breastfeed during the study or for 120 days after the last dose of study treatment",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "agreement to abstain",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration of abstention",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "during the study"
                                    },
                                    {
                                        "operator": "=",
                                        "value": 0,
                                        "unit": "for 120 days after the last dose of study treatment"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must be FEMALE",
            "criterions": [
                {
                    "exact_snippets": "Must be FEMALE",
                    "criterion": "sex",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "female"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Surgically sterile as defined as post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation. Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound. Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 180 days after the last dose of study treatment. Information must be captured appropriately within the site's source documents. Note: Abstinence is acceptable if this is the established and preferred contraception for the patient",
            "criterions": [
                {
                    "exact_snippets": "Surgically sterile as defined as post-hysterectomy, post-bilateral oophorectomy, or post-tubal ligation.",
                    "criterion": "surgical sterility",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "post-hysterectomy",
                                "post-bilateral oophorectomy",
                                "post-tubal ligation"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Documented hysterectomy or oophorectomy must be confirmed with medical records of the actual procedure or confirmed by an ultrasound.",
                    "criterion": "hysterectomy or oophorectomy documentation",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": [
                                "medical records of the actual procedure",
                                "confirmed by an ultrasound"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "Tubal ligation must be confirmed with medical records of the actual procedure, otherwise the patient must be willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 180 days after the last dose of study treatment.",
                    "criterion": "tubal ligation documentation or contraception",
                    "requirements": [
                        {
                            "requirement_type": "confirmation",
                            "expected_value": "medical records of the actual procedure"
                        },
                        {
                            "requirement_type": "alternative requirement",
                            "expected_value": "willing to use 2 adequate barrier methods throughout the study, starting with the screening visit through 180 days after the last dose of study treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "Abstinence is acceptable if this is the established and preferred contraception for the patient",
                    "criterion": "contraception method",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": "abstinence (if established and preferred)"
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Participant has had radiation therapy encompassing > 20% of the bone marrow within 2 weeks; or any radiation therapy within 1 week prior to day 1 of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "radiation therapy encompassing > 20% of the bone marrow within 2 weeks",
                    "criterion": "radiation therapy to bone marrow",
                    "requirements": [
                        {
                            "requirement_type": "extent",
                            "expected_value": {
                                "operator": ">",
                                "value": 20,
                                "unit": "% of bone marrow"
                            }
                        },
                        {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "any radiation therapy within 1 week prior to day 1 of protocol therapy",
                    "criterion": "any radiation therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since therapy",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "week"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant is considered a poor medical risk that would interfere with cooperation with the requirements of the study",
            "criterions": [
                {
                    "exact_snippets": "Participant is considered a poor medical risk that would interfere with cooperation with the requirements of the study",
                    "criterion": "medical risk",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "poor"
                        }
                    ]
                },
                {
                    "exact_snippets": "would interfere with cooperation with the requirements of the study",
                    "criterion": "ability to cooperate with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "ability",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have a known history of brain or leptomeningeal metastases",
            "criterions": [
                {
                    "exact_snippets": "must not have a known history of brain ... metastases",
                    "criterion": "brain metastases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have a known history of ... leptomeningeal metastases",
                    "criterion": "leptomeningeal metastases",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have previously progressed on PARP inhibitor",
            "criterions": [
                {
                    "exact_snippets": "must not have previously progressed on PARP inhibitor",
                    "criterion": "progression on PARP inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history of progression",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have had diagnosis, detection, or treatment of another type of cancer =< 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)",
            "criterions": [
                {
                    "exact_snippets": "diagnosis, detection, or treatment of another type of cancer =< 2 years prior to initiating protocol therapy (except basal or squamous cell carcinoma of the skin and cervical cancer that has been definitively treated)",
                    "criterion": "history of another type of cancer",
                    "requirements": [
                        {
                            "requirement_type": "time since diagnosis, detection, or treatment",
                            "expected_value": {
                                "operator": ">",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "exceptions",
                            "expected_value": [
                                "basal cell carcinoma of the skin",
                                "squamous cell carcinoma of the skin",
                                "cervical cancer that has been definitively treated"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have a history of interstitial lung disease",
            "criterions": [
                {
                    "exact_snippets": "must not have a history of interstitial lung disease",
                    "criterion": "history of interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant experienced >= grade 3 immune-related adverse event (AE) with prior immunotherapy, with the exception of non-clinically significant lab abnormalities",
            "criterions": [
                {
                    "exact_snippets": "Participant experienced >= grade 3 immune-related adverse event (AE) with prior immunotherapy",
                    "criterion": "immune-related adverse event with prior immunotherapy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 3,
                                "unit": "grade"
                            }
                        },
                        {
                            "requirement_type": "occurrence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has received a live vaccine within 30 days of initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "received a live vaccine within 30 days of initiating protocol therapy",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have received colony-stimulating factors (eg, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "must not have received colony-stimulating factors (eg, granulocyte colony-stimulating factor, granulocyte macrophage colony-stimulating factor, or recombinant erythropoietin) within 4 weeks prior initiating protocol therapy",
                    "criterion": "colony-stimulating factor administration",
                    "requirements": [
                        {
                            "requirement_type": "absence within time window",
                            "expected_value": {
                                "operator": "<",
                                "value": 4,
                                "unit": "weeks prior to initiating protocol therapy"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant's last treatment with platinum based chemotherapy was =< 4 weeks from initiation of protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "Participant's last treatment with platinum based chemotherapy was =< 4 weeks from initiation of protocol therapy",
                    "criterion": "time since last platinum based chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time interval",
                            "expected_value": {
                                "operator": "<=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have a serious, uncontrolled medical disorder, nonmalignant systemic disease, or active, uncontrolled infection. Examples include, but are not limited to, uncontrolled hypertension, uncontrolled ventricular arrhythmia, recent (within 90 days) myocardial infarction, uncontrolled major seizure disorder, unstable spinal cord compression, superior vena cava syndrome, or any psychiatric disorder that prohibits obtaining informed consent. Participants with hypertension but be well controlled before first dose of niraparib",
            "criterions": [
                {
                    "exact_snippets": "serious, uncontrolled medical disorder",
                    "criterion": "serious, uncontrolled medical disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "nonmalignant systemic disease",
                    "criterion": "nonmalignant systemic disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "active, uncontrolled infection",
                    "criterion": "active, uncontrolled infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled hypertension",
                    "criterion": "uncontrolled hypertension",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled ventricular arrhythmia",
                    "criterion": "uncontrolled ventricular arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "recent (within 90 days) myocardial infarction",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 90,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "uncontrolled major seizure disorder",
                    "criterion": "uncontrolled major seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable spinal cord compression",
                    "criterion": "unstable spinal cord compression",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "superior vena cava syndrome",
                    "criterion": "superior vena cava syndrome",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "any psychiatric disorder that prohibits obtaining informed consent",
                    "criterion": "psychiatric disorder prohibiting informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "Participants with hypertension but be well controlled before first dose of niraparib",
                    "criterion": "hypertension",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "well controlled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have a known hypersensitivity to niraparib and dostarlimab components or excipients",
            "criterions": [
                {
                    "exact_snippets": "must not have a known hypersensitivity to niraparib",
                    "criterion": "hypersensitivity to niraparib",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have a known hypersensitivity to ... dostarlimab components or excipients",
                    "criterion": "hypersensitivity to dostarlimab components or excipients",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has a diagnosis of immunodeficiency or has received systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "diagnosis of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has received systemic steroid therapy ... within 7 days prior to initiating protocol therapy",
                    "criterion": "systemic steroid therapy",
                    "requirements": [
                        {
                            "requirement_type": "received_within_days_prior",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "has received ... any other form of immunosuppressive therapy within 7 days prior to initiating protocol therapy",
                    "criterion": "immunosuppressive therapy (other than systemic steroids)",
                    "requirements": [
                        {
                            "requirement_type": "received_within_days_prior",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have any known history of myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML)",
            "criterions": [
                {
                    "exact_snippets": "must not have any known history of myelodysplastic syndrome (MDS)",
                    "criterion": "history of myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "must not have any known history of ... acute myeloid leukemia (AML)",
                    "criterion": "history of acute myeloid leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has a history of posterior reversible encephalopathy syndrome (PRES)",
            "criterions": [
                {
                    "exact_snippets": "history of posterior reversible encephalopathy syndrome (PRES)",
                    "criterion": "posterior reversible encephalopathy syndrome (PRES)",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have received investigational therapy =< 4 weeks, or within a time interval less than at least 5 half-lives of the investigational agent, whichever is longer, prior initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "must not have received investigational therapy =< 4 weeks",
                    "criterion": "receipt of investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "within a time interval less than at least 5 half-lives of the investigational agent",
                    "criterion": "receipt of investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "half-lives of the investigational agent"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not be simultaneously enrolled in any interventional clinical trial",
            "criterions": [
                {
                    "exact_snippets": "must not be simultaneously enrolled in any interventional clinical trial",
                    "criterion": "simultaneous enrollment in interventional clinical trial",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have had major surgery =< 3 weeks prior to initiating protocol therapy and participant must have recovered from any surgical effects",
            "criterions": [
                {
                    "exact_snippets": "must not have had major surgery =< 3 weeks prior to initiating protocol therapy",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since surgery",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participant must have recovered from any surgical effects",
                    "criterion": "recovery from surgical effects",
                    "requirements": [
                        {
                            "requirement_type": "recovery status",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs). Replacement hormone therapy (e.g., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not an exclusion criterion",
            "criterions": [
                {
                    "exact_snippets": "Participant has an active autoimmune disease that has required systemic treatment in the past 2 years (i.e., with use of disease-modifying agents, corticosteroids, or immunosuppressive drugs)",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "years"
                            }
                        },
                        {
                            "requirement_type": "treatment type",
                            "expected_value": [
                                "disease-modifying agents",
                                "corticosteroids",
                                "immunosuppressive drugs"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant must not have received a transfusion (platelets or red blood cells) =< 4 weeks prior to initiating protocol therapy",
            "criterions": [
                {
                    "exact_snippets": "must not have received a transfusion (platelets or red blood cells) =< 4 weeks prior to initiating protocol therapy",
                    "criterion": "transfusion (platelets or red blood cells)",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks prior to initiating protocol therapy"
                            }
                        },
                        {
                            "requirement_type": "receipt",
                            "expected_value": false
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has a known history of human immunodeficiency virus (type 1 or 2 antibodies)",
            "criterions": [
                {
                    "exact_snippets": "known history of human immunodeficiency virus (type 1 or 2 antibodies)",
                    "criterion": "human immunodeficiency virus (HIV) infection",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "type",
                            "expected_value": [
                                "type 1",
                                "type 2"
                            ]
                        },
                        {
                            "requirement_type": "antibody presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Participant has had any known grade 3 or 4 anemia, neutropenia or thrombocytopenia due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
            "criterions": [
                {
                    "exact_snippets": "grade 3 or 4 anemia ... due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
                    "criterion": "anemia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 3 or 4 neutropenia ... due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
                    "criterion": "neutropenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "grade 3 or 4 thrombocytopenia ... due to prior chemotherapy that persisted > 4 weeks and was related to the most recent treatment",
                    "criterion": "thrombocytopenia",
                    "requirements": [
                        {
                            "requirement_type": "grade",
                            "expected_value": [
                                "3",
                                "4"
                            ]
                        },
                        {
                            "requirement_type": "cause",
                            "expected_value": "prior chemotherapy"
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 4,
                                "unit": "weeks"
                            }
                        },
                        {
                            "requirement_type": "relation_to_treatment",
                            "expected_value": "most recent treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participant has known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive) or hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)",
            "criterions": [
                {
                    "exact_snippets": "known active hepatitis B (e.g., hepatitis B surface antigen [HBsAg] reactive)",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "diagnostic marker",
                            "expected_value": "hepatitis B surface antigen (HBsAg) reactive"
                        }
                    ]
                },
                {
                    "exact_snippets": "known active hepatitis C (e.g., hepatitis C virus [HCV] ribonucleic acid [qualitative] is detected)",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "diagnostic marker",
                            "expected_value": "hepatitis C virus (HCV) ribonucleic acid detected"
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}